Parkinson's disease (PD) is one of the most common neurodegenerative disorders that
manifest various motor and nonmotor symptoms. Although currently available therapies can …

Parkinson's disease is the second most common progressive neurodegenerative disease
diagnosed mainly based on clinical symptoms caused by loss of nigrostriatal dopaminergic …

Biomarkers and disease-modifying therapies are both urgent unmet medical needs in the
treatment of Parkinson's disease (PD) and must be developed concurrently because of their …

Parkinson's disease (PD) is a progressive neurodegenerative disorder that is diagnosed
largely on clinical grounds due to characteristic motor manifestations that result from the loss …

Parkinson's disease (PD) is a prevalent neurodegenerative illness that is often diagnosed
after significant pathology and neuronal cell loss has occurred. Biomarkers of PD are greatly …

Understanding the pathophysiology and genetic background of Parkinson's disease (PD)
increases the likelihood of developing effective disease-modifying therapeutic strategies. In …

Epigenetic mechanisms have emerged as important components of a variety of human
diseases, including cancer and central nervous system disorders. Despite recent studies …

Parkinson's disease is a neurodegenerative movement disorder characterized by loss of
midbrain dopaminergic neurons leading to motor abnormalities and autonomic dysfunctions …

Gene therapy has been employed in the human brain for a number of disorders in clinical
trials and may serve as an avenue for the treatment of Parkinson's disease (PD). Several …

Research on Parkinson's disease (PD) has made remarkable progress in recent decades,
due largely to new genomic technologies, such as high throughput sequencing and …